Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. - Wikidata - awgldk - TriplyDB

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

http://www.wikidata.org/entity/Q34624862

about

Pharmacogenomics in the clinic Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Cardiovascular pharmacogenomics: current status and future directions The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Clopidogrel and proton pump inhibitors--where do we stand in 2012?Pharmacogenetics and anaesthesia: the value of genetic profiling Application of routine electronic health record databases for pharmacogenetic research The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients Pharmacogenomics and cardiovascular disease Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation Pharmacogenomics of hypertension and heart disease Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade Genome-wide discovery of drug-dependent human liver regulatory elements Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association Genetics and cardiovascular disease: a policy statement from the American Heart Association.Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements.Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1 Use of genetic data to guide therapy in arterial disease.Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.Clinical pharmacogenetics implementation: approaches, successes, and challenges Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel Applied pharmacogenomics in cardiovascular medicine Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.Antiplatelet drug interactions with proton pump inhibitors Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?Implementation and utilization of genetic testing in personalized medicine.Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.Using models to predict the future: what to do when the data run out?Problems with the collection and interpretation of Asian-American health data: omission, aggregation, and extrapolation

P2860

Q26782786-BCC4DCAF-D0A4-46F1-A331-B1DDE4A75D3C Q26785321-9D0D3CEF-5F50-43E0-AD75-E16297363139 Q26787099-64B7E71D-2BBD-42D2-96FE-96A82D99E77E Q26801183-75B6C6A0-0F78-48A9-91E4-1F7379E412FD Q26801867-8F4938F0-CC2D-41A8-B9C8-00A2F092F237 Q26822796-F430E1A9-9F8D-463F-813B-6891DEA646D1 Q26823542-86C15B07-DB11-4158-AD1A-D523E957D16C Q26825728-862380F2-7B73-4659-BBD6-4BBC48B488EA Q26859221-7374D61C-2426-4DB8-B0D0-32E1A7C53FD6 Q26864747-A5D679BA-0C7E-4B31-9F5A-7CCCEC556884 Q26996594-5FBD9F80-36CA-45D9-86B7-5C776000EAE2 Q26997380-2B29971E-2BF4-46D2-A0A7-A25614DFF5E6 Q27011524-45606865-9825-4A48-8AFB-FC25A9584DDE Q27015722-ADAFA488-20DA-4432-9CF5-B95A3F4F5DDB Q27022443-02766BF7-61C0-4E71-BB7A-03194E810930 Q27022665-648946DC-3CE5-49CC-B084-E694190E14B5 Q28392069-9734B6F8-356F-4E7E-A066-87B19A65C1AF Q28543477-650733B0-42B9-4088-AD9F-F56F6A7A46A9 Q30359686-E20AC627-12CD-4119-BE64-50F8599215F6 Q30418104-3C5361CA-F37F-4209-A4ED-B2B772B0D583 Q30699715-7AE0E60C-927E-48CB-B727-94F58895E938 Q30840104-E2D17EE8-956C-4BC9-8FBE-9A6E17ECAE5D Q30978916-4B797289-6070-4832-91A9-5E66D228D900 Q33637840-02CC3C52-02A3-4942-BBEB-7F10F9171263 Q33792154-8C49FA4C-8F1F-448D-BC2F-FF648E09CFDC Q33825186-2811A243-AC23-4376-9CE0-15472CDD92D8 Q33837665-DCB3C3F6-F4EF-424E-BABC-FDBAAE3E9E6B Q33846255-70795FD4-B572-42E7-912F-DC25282EBFC4 Q33863833-6EB7CFF9-AA78-48CA-8699-F2790B3D5C2B Q33923341-7A9A3B39-30E6-4BC9-AFD8-572FFA2E515D Q33948811-FCF43529-973F-4D75-9A16-E9F5D1714F38 Q33963651-58258C99-FA4C-4D74-9C70-09E224086C67 Q33982372-308A8146-435A-4EB7-92D7-457642AFC2DE Q33988457-33360D85-D581-4489-9B09-A065F14683CD Q33997642-EF731BD2-5001-4C89-ADDB-9AC91AD39F0D Q34035039-4D61CDF8-AFF6-4B3F-998A-B2DDD5DC6DC3 Q34147916-CA436951-7B48-4043-9E6C-47C284FEEFC6 Q34161006-F8B6C83F-BF0E-4397-B653-E5E2C02748A4 Q34237664-A3FD705D-FFA8-40BB-98E2-818059525591 Q34280673-D0AC8BB7-B479-4405-A2C1-26D5E5D926AB

P2860

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

http://www.wikidata.org/entity/Q34624862

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@ast

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@en

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@nl

type

label

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@ast

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@en

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@nl

prefLabel

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@ast

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@en

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@nl

P1433

Q34624862-384765CD-E738-4927-833E-70706E8FCCC0

P1476

Q34624862-57AB19C0-E244-4ACC-9EA3-1A8AE31E8DE4

P2093

Q34624862-0F060151-795E-476C-947C-F05DEC92F17A

Q34624862-137A4D73-3781-48DD-9EA8-1B8C27620CC9

Q34624862-37A192E5-2F45-45F6-8FC1-F5E5DDE1DCC2

Q34624862-3F363697-6E90-4F55-B352-E5561D5DB849

Q34624862-49D87E00-81DD-40BB-BA43-0BD451F774E9

Q34624862-72939443-EAF3-4CF5-8AC7-B5F59555839A

Q34624862-A19D3FC9-A4E5-4DE5-B048-14F1F5EE0CC5

Q34624862-AA5AACC4-80C3-4B9B-998E-30B3D4E0B9D1

Q34624862-C062B5F5-142E-4EF9-8F6E-ECE9E9FAE780

Q34624862-C346BC6F-27B3-44C7-9412-601C201BAC3E

P2860

Q34624862-0E787A29-EAEB-494B-966C-D2E3CFFA7DAC

Q34624862-1349AEEE-91D3-433C-870D-B31B0FD5C608

Q34624862-1986474F-C507-4B18-A1A3-75C2B5B012C9

Q34624862-1A9782D4-8C2D-4E88-8484-94F08A617CA7

Q34624862-1B029A0F-88A4-4E43-8C36-73C2EF272613

Q34624862-1D6F7F9F-6FF7-4433-B80E-D37A10D01ABF

Q34624862-1FC60F2B-48E0-4E8F-97D8-235AEC4AD32C

Q34624862-26E2D457-B0C1-4EDD-AD00-3DE3CC78BF34

Q34624862-37A790FC-E269-46BE-BE02-A482140643FF

Q34624862-3E0D36F9-355B-4FC8-93BE-9C95316387A3

P304

Q34624862-5E18D485-034D-495D-B4BE-7C1541FBD3ED

P31

Q34624862-2E00DBD8-CF0A-4609-82D3-572B89EA5F42

Q34624862-7511790f-293f-4963-abfd-26447c9659cb

P356

Q34624862-9DEBF855-3398-4FAE-8E52-0CACF156EE01

P407

Q34624862-E3C2E2B4-B6A0-4220-8E25-2BE51C167286

P433

Q34624862-51376016-9FDC-4B8C-B058-F37989D981DC

P478

Q34624862-C64F632A-D1A4-4F1D-8308-F5115CF60B79

P50

Q34624862-54F68A7E-A037-4520-9B16-1F6FF6A602E2

Q34624862-942AC205-62AC-44E1-83DF-4F4F3ACBA65E

Q34624862-C08B9C46-790C-462F-8D64-E63EACB88C83

Q34624862-D3B5B5BE-715C-400B-8144-889EEBB84002

Q34624862-E4ABB025-F22A-45A6-9700-25E4EDF5AC39

P577

Q34624862-04609B04-BB01-4AD9-9C7F-2587F0770E21

P5875

Q34624862-76F7932C-758F-4363-81D2-9538E17EACE4

P698

Q34624862-8320EE59-57C2-4DD3-8162-E36765754A19

P921

Q34624862-69121353-061B-4D3A-9205-0FA602B58A77

Q34624862-DC357CE8-4ECC-4968-A4E8-138EBE938EC1

Q34624862-E273655C-0F84-443E-94DA-46DF17BE6603

P932

Q34624862-3BF5E34F-816E-48A7-A60D-0901F9943126

P356

P1433

Journal of the American Medical Association

P1476

Reduced-function CYP2C19 genot ...... ntly for PCI: a meta-analysis.

@en

P2093

Benjamin D Horne

http://www.w3.org/2001/XMLSchema#string

Christopher P Cannon

http://www.w3.org/2001/XMLSchema#string

Dietmar Trenk

http://www.w3.org/2001/XMLSchema#string

Dirk Sibbing

http://www.w3.org/2001/XMLSchema#string

Franz-Josef Neumann

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Collet

http://www.w3.org/2001/XMLSchema#string

Jean-Sebastian Hulot

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Anderson

http://www.w3.org/2001/XMLSchema#string

Jessica L Mega

http://www.w3.org/2001/XMLSchema#string

Kevin Bliden

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.

Meta-analysis in clinical trials

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

Stent thrombosis in randomized clinical trials of drug-eluting stents

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

P304

1821-1830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2010.1543

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

304

http://www.w3.org/2001/XMLSchema#string

P50

Gilles Montalescot

Tabassome Simon

Elliott M Antman

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47556097

http://www.w3.org/2001/XMLSchema#string

P698

20978260

http://www.w3.org/2001/XMLSchema#string

P921

P932

3048820

http://www.w3.org/2001/XMLSchema#string